AVITA Medical Inc
NASDAQ:RCEL

Watchlist Manager
AVITA Medical Inc Logo
AVITA Medical Inc
NASDAQ:RCEL
Watchlist
Price: 11.77 USD 2.53% Market Closed
Market Cap: 308.6m USD
Have any thoughts about
AVITA Medical Inc?
Write Note

AVITA Medical Inc
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

AVITA Medical Inc
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
AVITA Medical Inc
NASDAQ:RCEL
Cost of Revenue
-$7.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cost of Revenue
-$18.2B
CAGR 3-Years
-1%
CAGR 5-Years
-19%
CAGR 10-Years
-15%
Gilead Sciences Inc
NASDAQ:GILD
Cost of Revenue
-$6.3B
CAGR 3-Years
-5%
CAGR 5-Years
-7%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Cost of Revenue
-$12.9B
CAGR 3-Years
-27%
CAGR 5-Years
-25%
CAGR 10-Years
-13%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cost of Revenue
-$1.5B
CAGR 3-Years
-20%
CAGR 5-Years
-25%
CAGR 10-Years
-36%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cost of Revenue
-$1.8B
CAGR 3-Years
0%
CAGR 5-Years
-22%
CAGR 10-Years
-25%
No Stocks Found

AVITA Medical Inc
Glance View

Market Cap
308.6m USD
Industry
Biotechnology

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. The company is headquartered in Valencia California, California. The company went IPO on 2012-03-18. The firm is engaged in developing and commercializing a technology platform, which enables point-of-care autologous skin restoration for multiple unmet needs. The company provides treatment solutions derived from the regenerative properties of a patient’s own skin. Its RECELL Autologous Cell Harvesting System (RECELL) enables clinicians to prepare Spray-On Skin Cells, an autologous skin cell suspension, which is sprayed onto the patient to regenerate natural healthy skin. The RECELL System is a single use disposable, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators to achieve the disaggregation and delivery of skin cells. The platform technology of the RECELL System allows for the preparation and delivery of Spray-On Skin Cells, an autologous cellular suspension comprised of the patient’s own skin cells.

RCEL Intrinsic Value
15.68 USD
Undervaluation 25%
Intrinsic Value
Price

See Also

What is AVITA Medical Inc's Cost of Revenue?
Cost of Revenue
-7.6m USD

Based on the financial report for Dec 31, 2023, AVITA Medical Inc's Cost of Revenue amounts to -7.6m USD.

What is AVITA Medical Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
-33%

Over the last year, the Cost of Revenue growth was -33%.

Back to Top